Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL444915 | 1.00 | MME (0.41) | MMERAB9AACECPA1ACE2 | |
| SCHEMBL194101 | 1.00 | MME (0.41) | MMERAB9AACECPA1ACE2 | |
| SCHEMBL7324309 | 0.91 | MME (0.44) | MMERAB9AACECPA1ACE2 | |
| Alanine SCHEMBL2176579 | 0.91 | MME (0.36) | MMERAB9AACECPA1ACE2 | |
| SCHEMBL7324302 | 0.91 | MME (0.44) | MMERAB9AACECPA1ACE2 | |
| SCHEMBL204822 | 0.87 | SMN1; SMN2 (0.40) | SMN1; SMN2TYRALDH1A1CA2CA1 | |
| SCHEMBL29613052 | 0.81 | MME (0.41) | MMEACECPA1ACE2SMN1; SMN2 | |
| Aspartic Acid SCHEMBL7173783 | 0.81 | SLC7A5 (0.42) | — | |
| SCHEMBL23766673 | 0.80 | HTT (0.43) | MMERAB9AACECPA1ACE2 | |
| SCHEMBL3507245 | 0.80 | TGFBR1 (0.55) | MMERAB9AACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 567 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024017317-A1 | HER2 TARGETING PEPTIDE MOLECULE AND USE THEREOF | 中国科学院上海药物研究所 | 2024-01-25 | — | — | WO | claimed |
| CN-122055369-A | Bridged tricyclic carbamoyl pyridone compounds and uses thereof | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12496282-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| WO-2025080863-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20250122219-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-04-17 | — | — | US | disclosed |
| US-20240366538-A1 | Hepatitis B Antiviral Agents | ENANTA PHARM INC (US) | 2024-11-07 | — | — | US | disclosed |
| US-12011425-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| CN-114437714-B | Circular polarization luminescent material based on enantioselective co-assembly and application thereof | 中国科学院化学研究所 | 2023-09-29 | — | — | CN | disclosed |
| US-20230241012-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2023-08-03 | — | — | US | disclosed |
| EP-3473639-B1 | HEPATITIS C VIRUS INHIBITOR AND APPLICATION | ZHEJIANG PALO ALTO PHARMACEUTICALS INC (CN) | 2023-03-29 | — | — | EP | disclosed |
| EP-0623592-B1 | Peptide analogs as irreversible interleukin-1beta protease inhibitors | VERTEX PHARMA (US) | 2001-06-27 | — | — | EP | disclosed |
| US-5985838-A | TREATING INFECTIOUS DISEASE, RESPIRATORY DISEASE, INFLAMMATORY CONDITIONS, IMMUNE-BASED DISEASE, AUTO-IMMUNE DISEASE, BONE DISEASE, AND TUMORS | VERTEX PHARMACEUTICALS, INC. (US) | 1999-11-16 | — | — | US | disclosed |
| US-5466858-A | Ruthenium catalyst, high selectivity with a carboxylic acid | UBE INDUSTRIES, LTD. (JP) | 1995-11-14 | — | — | US | disclosed |
| EP-0623592-A1 | Peptide analogs as irreversible interleukin-1beta protease inhibitors | STERLING WINTHROP INC. (US) | 1994-11-09 | — | — | EP | disclosed |
| US-5079167-A | Enzymatic resolution of amino acid carbamate racemates | GESELLSCHAFT FUR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) (DE) | 1992-01-07 | — | — | US | disclosed |
| EP-0243606-A1 | Process for enzymatic racemate cleavage | Gesellschaft für Biotechnologische Forschung mbH (GBF) (DE) | 1987-11-04 | — | — | EP | disclosed |
| WO-1987005329-A1 | PROCESS FOR THE SEPARATION OF RACEMATES | GESELLSCHAFT FÜR BIOTECHNOLOGISCHE FORSCHUNG MBH ( (DE) | 1987-09-11 | — | — | WO | disclosed |
| US-4618710-A | Preparation of optically active ketones | THE REGENTS OF THE UNIVERSITY OF CALIF. (US) | 1986-10-21 | — | — | US | disclosed |
| US-4496755-A | Optically active 1-(6-methoxy-2-naphthyl)-2-(alkoxycarbonyl) amino-1-propanone, its derivatives and their halo analogs and the methods for their manufacture | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1985-01-29 | — | — | US | disclosed |
| EP-0091757-A1 | Optically active 1-(6-methoxy-2-naphthyl)-2-alkoxycarbonyl)amino-1-propanone, its derivatives and their halo anlogs, and methods for their manufacture | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1983-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122219-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SDHA, SDHB, DPYD | MME 2896/4885RAB9A 1147/4885ACE 203/4885 |
| US-20230241012-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | MME 1280/4885RAB9A 969/4885ACE 495/4885 |
| US-12011425-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | MME 1280/4885RAB9A 969/4885ACE 495/4885 |
| US-20240366538-A1 | Hepatitis B Antiviral Agents | HAVCR2, PYGL, SLC10A1 | MME 1280/4885RAB9A 969/4885ACE 495/4885 |
| US-12496282-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | MME 1280/4885RAB9A 969/4885ACE 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.